Amniotics

Mindre end 1K følgere

Amniotics udvikler og producerer stamcelleterapier i deres eget GMP-certificerede anlæg. Amniotics blev født ud af opdagelsen af en ny kilde til stamceller i fuldtids fostervand. Baseret på ti års forskning ved det internationalt anerkendte Lund University Stamcelle Center og Hospital, er virksomheden banebrydende inden for høst og formering af vævsspecifikke neonatale kvalitet mesenchymale stamceller (MSC). Virksomheden er noteret på Nasdaq First North Growth Market i Stockholm.

Alle

Analyse

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse23.9.2024, 11.30

The Swedish Companies Registration Office has authorised the implementation of the merger plan between Magle group and Amniotics

Pressemeddelelse20.8.2024, 11.27

Redeye: Amniotics H1 2024 - Merger with Magle

Selskabsmeddelelse6.8.2024, 08.45

Amniotics receives conditional approval to delist from Nasdaq First North Growth Market

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse6.8.2024, 06.45

Amniotics applies for delisting from Nasdaq First North Growth Market conditional upon completion of the merger with Magle Group

Selskabsmeddelelse1.7.2024, 15.30

Amniotics publishes merger document regarding the merger with Magle Group

Selskabsmeddelelse30.5.2024, 18.05

Statement from the Board of Directors of Amniotics regarding the merger with Magle Group

Selskabsmeddelelse30.5.2024, 18.00

Magle Group and Amniotics merge to create a leader in high-quality life-changing healthcare innovations with a broadened CDMO offering

Selskabsmeddelelse21.5.2024, 19.50

Amniotics secures continued short-term capital needs by extending loan agreement and continued services under service agreement

Selskabsmeddelelse22.3.2024, 06.40

Statement from the Board of Directors of Amniotics regarding the public offer from Magle Chemoswed

Selskabsmeddelelse21.3.2024, 17.00

Amniotics secures short-term capital needs by extending loan agreement and entering into a service agreement

Selskabsmeddelelse11.3.2024, 15.00

Amniotics announces the outcome of the exercise of warrants series TO 3

Selskabsmeddelelse26.2.2024, 07.30

The exercise period for warrants series TO 3 in Amniotics begins today

Pressemeddelelse26.2.2024, 06.57

Redeye: Amniotics Q4 2023 - Investigator-sponsored trial in lung transplantation needs funding

Selskabsmeddelelse22.2.2024, 14.05

Amniotics AB (publ) Report for the fourth quarter 2023.

Pressemeddelelse21.12.2023, 13.16

Information about the Annual General Meeting and appointed Nomination Committee of Amniotics

Selskabsmeddelelse14.12.2023, 10.20

Amniotics receives orphan designation for PulmoStem® from the European Commission for the Treatment of Primary Graft Dysfunction following Lung Transplantation

Pressemeddelelse28.11.2023, 07.30

Redeye: Amniotics Q3 2023 - Rights Issue Foundation for Lung Transplantation Study

Selskabsmeddelelse27.11.2023, 07.00

Amniotics AB (publ) Report for the third Quarter 2023

Pressemeddelelse23.11.2023, 11.00

Renewed GMP certification

Selskabsmeddelelse20.11.2023, 14.40

Amniotics receives positive opinion on orphan designation for PulmoStem® from the European Medicines Agency for the Treatment of Primary Graft Dysfunction following Lung Transplantation

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.